RFM
CBIO

Royal Fund Management’s Crescent Biopharma CBIO Stock Holding History

Royal Fund Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-4
Closed -$6K – 587
2017
Q4 		$6K Buy
+4
New +$5.29K ﹤0.01% 445

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royal Fund Management's CBIO Position: Q1 2018 in Review

Royal Fund Management sold out of Crescent Biopharma (CBIO) in Q1 2018, closing a stake of 4 shares — an estimated $6K sold.

Royal Fund Management first reported a position in CBIO in Q4 2017 and held it in 1 quarter. The position peaked at $6K in Q4 2017. 84 funds tracked by Wall St. Rank hold CBIO as of Q1 2018.

  • Royal Fund Management reported no remaining Crescent Biopharma position as of Q1 2018 after selling out during the quarter.
  • Royal Fund Management sold 4 Crescent Biopharma shares in Q1 2018, an estimated $6K.
  • Royal Fund Management first reported a position in Crescent Biopharma in Q4 2017 and held it in 1 quarter.
  • Royal Fund Management's Crescent Biopharma position peaked at $6K in Q4 2017.
  • 84 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2018.

Based on Royal Fund Management's 13F filing for Q1 2018, filed 7 May 2020.